Bond.az reports that Eisai has unveiled its new three-year strategic plan.
The presentation style shifted, featuring COO Keisuke Naito, CSO Katsutoshi Ido, and CFO Takuya Oyama, instead of CEO Haruo Naito.
Targets: ¥1 trillion in sales and ¥90 billion in operating profit by March 2029.
Sales breakdown: ¥300 billion for Leqembi, ¥250 billion for Lenvima, ¥100 billion for Dayvigo.
Consensus estimates: ¥972 billion sales and ¥101.8 billion operating profit. Sales are in line, but profit falls short.
Eisai projects a 30% cost of goods sold ratio, versus consensus of 23%, due to expected product mix changes.
Citi analyst Hidemaru Yamaguchi called the plan "a transition from a bullish stance to a conservative one."
He noted the high CoGS ratio as somewhat negative.
